Johnson & Johnson JNJ announced positive top-line data from a late-stage study evaluating the combination of niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, plus prednisone ...

ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Sharon Choi discussing comprehensive genomic profiling of Black and non-Hispanic White men with prostate cancer. Racial ...

ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST           U.S. FDA approves third indication of darolutamide for patients with ...

The score ranges from 6 to 10 because grades 1 and 2 are rarely used for cancer diagnosis. (a score of 1-2 means that you do ...

Kicking off the summit, participants immersed themselves in a hands‑on workshop on three‑dimensional (3D) brachytherapy planning. Under the guidance of experienced medical physicists, radiation ...

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to ...